Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2026-01-03 @ 7:05 AM
Study NCT ID:
NCT04223856
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-13
First Post:
2020-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-03-30
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-03-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-01-06
First Submit QC Date:
None
Study First Post Date:
2020-01-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-07-30
Results First Submit QC Date:
None
Results First Post Date:
2024-09-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-04
Last Update Post Date:
2025-06-13
Last Update Post Date Type:
ACTUAL